Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Guide · Medicaid · United States
Does Medicaid cover GLP-1s for weight loss? Coverage by state
In most states, no: as of October 30, 2026, 10 of the 51 Medicaid programs in the 50 states and DC cover GLP-1s such as Wegovy and Zepbound for weight loss, 2 of them with much tighter criteria than the label. Every state still covers these medicines for some other approved uses, such as Zepbound for sleep apnea and Wegovy for heart risk, with prior authorization, and several states ended weight-loss coverage in 2026.
Every row carries its source and date; we read them on October 30, 2026. This is general information, not advice about your plan or your health: a clinician decides whether a medicine is right for you, and your state's Medicaid program decides coverage.
Recent changes
- Rhode Island: October 1, 2026. Ended weight-loss-only coverage of Foundayo, Saxenda, Wegovy and Zepbound. Other approved uses and under-21s remain covered. Source: Point32Health RITogether notice (September 2026).
- Indiana: Announced July 30, 2026; start not confirmed. Announced it will join the CMS BALANCE model and cover GLP-1s for obesity. Pending: the start date and criteria have not been published. Source: Indiana Public Media (July 30, 2026).
- Massachusetts: July 3, 2026. MassHealth stopped covering anti-obesity drugs for weight loss, including Wegovy and Zepbound. Coverage stays, with prior authorization, for cardiovascular, MASH and sleep apnea uses and under-21s. Source: MassHealth Prescriber e-Letter (March 2026, corrected).
- Utah: Likely June 30, 2026 (not confirmed). The weight-loss pilot was funded for fiscal year 2026 only. A secondary source says coverage ended on June 30, 2026; no primary source confirms it. Source: KFF (January 16, 2026).
- Louisiana: Pending funding. A law (SB 433) requires Medicaid to cover FDA-approved weight-loss drugs once it is funded; the fiscal note assumes January 1, 2027. Not live yet. Source: Louisiana Legislative Fiscal Office (June 1, 2026).
Medicaid GLP-1 coverage for weight loss, state by state
Status as of October 30, 2026. "Yes" means the program covers GLP-1s for obesity with prior authorization; "Limited" means its criteria are much tighter than the label; "No (KFF)" means the state was not among the 13 fee-for-service programs KFF counted as covering in January 2026 and we found no change since. KFF counts fee-for-service only, so managed care plans may differ. Every state still covers other approved uses, subject to its own prior authorization.
| State | Covers GLP-1s for weight loss? | Criteria | Source | Date |
|---|---|---|---|---|
| Alabama | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Alaska | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Arizona | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Arkansas | No (KFF) | None stated | KFF | Jan 16, 2026 |
| California | No (ended Jan 1, 2026) | Case-by-case prior authorization for Wegovy (MASH or cardiovascular disease), Zepbound (sleep apnea) and under-21s (EPSDT) | Medi-Cal Rx alert | Oct 21, 2025 |
| Colorado | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Connecticut | No (KFF) | Covers some non-GLP-1 weight-loss drugs | KFF | Jan 16, 2026 |
| Delaware | Yes | BMI over 30, or over 27 with a related condition (type 2 diabetes, heart disease, high blood pressure, high cholesterol or sleep apnea). Lifestyle program required. 6-month approvals; renewal needs at least 5% weight loss. Saxenda, liraglutide, Wegovy, Zepbound. From a managed care plan policy aligned to the state plan. | Delaware First Health policy; KFF | reviewed Apr 2026; Jan 16, 2026 |
| District of Columbia | Not confirmed | KFF's text does not mention DC, and no DHCF source was found | None found | None |
| Florida | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Georgia | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Hawaii | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Idaho | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Illinois | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Indiana | No; planned via BALANCE (not confirmed live) | Announced Jul 30, 2026. Start date and criteria not published. | Indiana Public Media | Jul 30, 2026 |
| Iowa | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Kansas | Yes (KFF) | Criteria not verified | KFF | Jan 16, 2026 |
| Kentucky | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Louisiana | No (KFF); law pending funding | Covers some non-GLP-1 weight-loss drugs. SB 433 (enrolled) takes effect only when funded; the fiscal note assumes Jan 1, 2027. Signature not confirmed. | Louisiana Legislative Fiscal Office note; KFF | Jun 1, 2026; Jan 16, 2026 |
| Maine | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Maryland | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Massachusetts | Ended Jul 3, 2026 | Still covered with prior authorization: cardiovascular (BMI over 27 with cardiovascular disease), MASH, sleep apnea (BMI over 30), under-21s (EPSDT) | MassHealth Prescriber e-Letter | Mar 2026 (corrected) |
| Michigan | Limited | Since Jan 1, 2026: "morbidly obese" only (no numeric BMI given), after all other interventions including preferred anti-obesity drugs have failed, to avoid bariatric surgery | MDHHS Numbered Letter L 25-73 | Dec 8, 2025 |
| Minnesota | Yes (KFF) | DHS prior authorization criteria page modified Aug 4, 2026; its body text could not be read | KFF; Minnesota DHS criteria page | Jan 16, 2026; modified Aug 4, 2026 |
| Mississippi | Yes | Adults: BMI 30 or higher, or 27 to 29 with a related condition. Foundayo, Saxenda, Wegovy and Zepbound preferred. Lifestyle program and treatment plan required. 12-month approvals; renewal needs at least 5% weight loss. Members with Part D must use Part D first. | Mississippi Medicaid criteria | Jul 1, 2026 |
| Missouri | Yes (KFF) | Criteria not verified | KFF | Jan 16, 2026 |
| Montana | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Nebraska | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Nevada | No (KFF) | None stated | KFF | Jan 16, 2026 |
| New Hampshire | No (ended Jan 1, 2026) | Covers some non-GLP-1 weight-loss drugs | KFF; Milliman | Jan 16, 2026; Mar 19, 2026 |
| New Jersey | No (KFF) | None stated | KFF | Jan 16, 2026 |
| New Mexico | No (KFF) | Covers some non-GLP-1 weight-loss drugs | KFF | Jan 16, 2026 |
| New York | No (KFF) | None stated | KFF | Jan 16, 2026 |
| North Carolina | Yes | Reinstated Dec 12, 2025 under the Aug 1, 2024 prior authorization criteria. Wegovy preferred; Zepbound and Saxenda need a Wegovy trial first. | NC Medicaid | Dec 19, 2025 |
| North Dakota | No (KFF) | Covers some non-GLP-1 weight-loss drugs | KFF | Jan 16, 2026 |
| Ohio | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Oklahoma | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Oregon | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Pennsylvania | No for adults 21+ (ended Jan 1, 2026) | Under-21s (EPSDT) continue; type 2 diabetes, sleep apnea, cardiovascular and MASH uses covered with prior authorization | PHLP; KFF | Dec 22, 2025; Jan 16, 2026 |
| Rhode Island | Ended Oct 1, 2026 | Wegovy (cardiovascular or MASH), Zepbound (sleep apnea), type 2 diabetes GLP-1s and under-21s (EPSDT) remain covered | Point32Health RITogether notice; American Diabetes Association | Sep 2026; Jun 25, 2026 |
| South Carolina | No (ended; Jan 1, 2026 per Milliman) | None stated | KFF; Milliman | Jan 16, 2026; Mar 19, 2026 |
| South Dakota | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Tennessee | Yes | Adults: BMI 30 or higher, or 27 or higher with a related condition (high blood pressure, high cholesterol, diabetes, heart disease, MASH or sleep apnea). Wegovy and Zepbound preferred, with prior authorization. Lifestyle attestation; renewal needs at least 5% weight loss. | TennCare / OptumRx provider notice | effective Aug 1, 2025 |
| Texas | No (KFF) | Covers some non-GLP-1 weight-loss drugs | KFF | Jan 16, 2026 |
| Utah | Not confirmed (likely ended Jun 30, 2026) | KFF: funding limited to fiscal year 2026. The state's prior authorization form (last updated Jul 1, 2025): BMI 30 or higher, or 27 to 29.9 with a related condition, plus a 6-month dietitian-led lifestyle program. No primary source confirms the end. | KFF; Utah Medicaid PA form | Jan 16, 2026; Jul 1, 2025 |
| Vermont | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Virginia | Limited | GLP-1s: BMI over 40, or over 37 with high cholesterol, high blood pressure or type 2 diabetes. One non-GLP-1 weight-loss drug must fail first, plus a preferred drug list step. | DMAS weight loss PA form | revised Apr 16, 2026 |
| Washington | No (KFF) | None stated | KFF | Jan 16, 2026 |
| West Virginia | No (KFF) | None stated | KFF | Jan 16, 2026 |
| Wisconsin | Yes | Adults: BMI 30 or higher, or 27 to under 30 with two related conditions. A weight-loss plan in the prior 6 months. A July 2026 criteria update was reported by a secondary source and is not confirmed. | Wisconsin ForwardHealth PA form; KFF | form Jul 2024; Jan 16, 2026 |
| Wyoming | No (KFF) | None stated | KFF | Jan 16, 2026 |
In total: 10 programs cover (8 yes, 2 limited), 6 ended coverage in 2026 with a confirmed date, Indiana and Louisiana are pending and not live, and District of Columbia and Utah are not confirmed. KFF's state list is from its map, via the Pew Research Center chart (January 23, 2026).
For Zepbound on its own, see does Medicaid cover Zepbound?, which lists the states whose criteria name it and what stays covered for sleep apnea.
How Medicaid GLP-1 coverage works
- Weight-loss coverage is optional for states. Every covering state above uses prior authorization, so your prescriber applies for you.
- Several states add conditions: a documented lifestyle program (Mississippi, Utah, Wisconsin), at least 5% weight loss to renew (Delaware, Mississippi, Tennessee, Utah) or trying other medicines first (Virginia, Michigan).
- Where the manufacturer has a rebate agreement, states must cover Zepbound for obstructive sleep apnea (CMS, January 2025) and Wegovy for cardiovascular risk reduction (CMS, March 2024). They do not have to cover either for weight loss.
- The CMS BALANCE model lets states opt in, from May 2026 through January 1, 2027, to cover Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen and Foundayo for weight management under negotiated criteria, including prior authorization; coverage is not guaranteed. CMS's page lists no participating state yet. Indiana has announced it will join; its start date is not confirmed.
Sources: KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026); NBC San Diego / CNBC: Medicare can now cover Zepbound for sleep apnea, CMS says (January 8, 2025); Managed Healthcare Executive: Medicaid, Medicare Part D to provide coverage of Wegovy, but not for weight loss (March 22, 2024); CMS: BALANCE model (page last modified September 29, 2026); CMS press release: CMS launches voluntary model to expand access to life-changing medicines (December 23, 2025); Milliman: The evolving landscape of obesity coverage in Medicaid (March 19, 2026). Read October 30, 2026.
If you have Medicare and Medicaid
People with both can use the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) if they have qualifying Part D coverage, including a Dual Eligible Special Needs Plan, and meet its criteria. The copay is the full $50 a month, because Extra Help does not apply to Bridge drugs. Whether your state Medicaid program pays that copay varies: Pennsylvania's will not (PHLP, June 26, 2026), and Mississippi requires members with Part D to use Part D first and does not cover Part D copays (Mississippi criteria, July 1, 2026). Missouri issued a policy on Bridge copays on July 8, 2026, but its content is not confirmed.
Sources: Medicare.gov: Weight loss drugs (no page date); CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); PHLP: New Medicare program to offer limited coverage for GLP-1 weight loss medications (June 26, 2026). Read October 30, 2026.
If your state does not cover it
If you also have Medicare, see whether you qualify for the Bridge: does Medicare cover Wegovy and does Medicare cover Zepbound. Otherwise, the manufacturers sell both medicines direct for cash, with a prescription you already hold. We list these prices for information; PCF has no commercial relationship with either manufacturer.
- NovoCare Pharmacy lists the Wegovy pill at $149 a month at the starting dose, checked November 19, 2026. No membership printed, prescription required. NovoCare Pharmacy's page
- NovoCare Pharmacy lists the Wegovy pen at $199 a month at the starting dose ("Offer is for 2 monthly fills through December 31, 2026"; then $349 per month), checked November 19, 2026. No membership printed, prescription required. NovoCare Pharmacy's page
- LillyDirect lists the Zepbound KwikPen at $299 a month at the starting dose, checked November 19, 2026. No membership printed, pen needles sold separately, prescription required. LillyDirect's page
- LillyDirect lists the Zepbound vial at $299 a month at the starting dose, checked November 19, 2026. No membership printed, needles and syringes sold separately, prescription required. LillyDirect's page
Frequently asked questions
Does Medicaid cover Wegovy for weight loss?
Only in some states. As of October 30, 2026, 10 state Medicaid programs cover GLP-1s such as Wegovy for weight loss (2 with much tighter criteria), all with prior authorization. Every state must cover Wegovy for cardiovascular risk reduction where the manufacturer has a rebate agreement (CMS, March 2024). See the table for your state.
Does Medicaid cover Zepbound for weight loss?
Only in some states, the same 10 programs, with prior authorization. Every state must cover Zepbound for obstructive sleep apnea where the manufacturer has a rebate agreement (CMS, January 2025), but not for weight loss.
Which states stopped covering GLP-1s for weight loss in 2026?
California, New Hampshire, Pennsylvania (adults 21 and over) and South Carolina from January 1, 2026, Massachusetts from July 3, 2026 and Rhode Island from October 1, 2026. Utah's coverage was funded for fiscal year 2026 only and likely ended on June 30, 2026, but no primary source confirms it.
Is any state adding coverage?
Indiana announced on July 30, 2026 that it will join the CMS BALANCE model and cover GLP-1s for obesity, but its start date and criteria are not published. Louisiana passed a law requiring coverage once it is funded; the fiscal note assumes January 1, 2027. Neither is live.
What is the BALANCE model?
A voluntary CMS model that states can join from May 2026 through January 1, 2027 to cover Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen and Foundayo for weight management under negotiated criteria, including prior authorization. CMS's page (September 29, 2026) names no participating state yet.
I have Medicare and Medicaid. Can I use the Medicare GLP-1 Bridge?
Yes, if you have qualifying Part D coverage and meet the criteria. You still pay the full $50 a month, because Extra Help does not apply to Bridge drugs. Whether your state Medicaid program pays that copay varies: Pennsylvania's will not (PHLP, June 26, 2026).
Main sources
- KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026)
- Pew Research Center: Most states don't cover GLP-1s for obesity treatment under Medicaid (January 23, 2026)
- Milliman: The evolving landscape of obesity coverage in Medicaid (March 19, 2026)
- CMS: BALANCE model (page last modified September 29, 2026)
- The Lund Report (Stateline): More states consider dropping GLP-1 weight loss drugs from Medicaid (May 5, 2026)